ClinConnect ClinConnect Logo
Search / Trial NCT07069153

Laser vs Ozone Therapy for Oral Mucositis in Cancer Patients

Launched by UNIVERSITY OF PAVIA · Jul 5, 2025

Trial Information

Current as of July 21, 2025

Not yet recruiting

Keywords

Oral Mucositis Cancer Pain Laser Therapy Ozone Therapy Photobiomodulation Head And Neck Cancer Hematologic Malignancies Chemotherapy Radiotherapy Supportive Care In Oncology

ClinConnect Summary

This clinical trial is studying two different treatments—laser therapy and ozone therapy—to help reduce the pain and mouth sores caused by oral mucositis, a common side effect of cancer treatments like chemotherapy and radiation. Oral mucositis causes painful ulcers in the mouth that can make eating, speaking, and keeping the mouth clean very difficult. The study aims to find out which treatment works better to ease these symptoms and improve patients’ quality of life.

Adults with head and neck cancer or blood cancers who are currently receiving chemotherapy or radiation and have moderate to severe mouth sores may be eligible to join. If you participate, you will be randomly assigned to receive either laser therapy or ozone therapy once a day for five days. The treatments are painless and done using special devices inside the mouth. You will be checked at 15 and 30 days after starting treatment to see how well the sores and pain have improved. The study will also look at how these treatments affect your overall comfort and daily life during cancer care.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥18 years
  • Diagnosis of head and neck cancer or hematologic malignancy
  • Currently undergoing chemotherapy and/or radiotherapy
  • Presence of oral mucositis of grade 2 or higher (WHO Oral Mucositis Scale)
  • Ability to provide written informed consent
  • Willingness to comply with study procedures and follow-up schedule
  • Exclusion Criteria:
  • Presence of autoimmune or systemic diseases affecting the oral mucosa (e.g., lichen planus, pemphigus, pemphigoid)
  • Presence of active oral infections unrelated to mucositis (e.g., candidiasis, herpes simplex)
  • Previous treatment with ozone or laser therapy for oral mucositis in the past 3 months
  • Pregnancy or breastfeeding
  • Cognitive impairment or psychiatric disorders preventing full cooperation
  • Known allergy or intolerance to ozone or laser exposure
  • Use of investigational drugs or participation in other clinical trials within 30 days prior to enrollment

About University Of Pavia

The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.

Locations

Pavia, Lombardy, Italy

Patients applied

0 patients applied

Trial Officials

Andrea Scribante, Associate Professor

Principal Investigator

University of Pavia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported